Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Enrolling by invitation · Phase 3

Conditions studied: Migraine

In brief

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in pediatric participants. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Pediatric participants (aged 6-17 years) with a history of migraine will be enrolled. Participants who completed the lead-in Study 3110-305-002, as well as those who were placebo responders and screen failed, will be eligible to enroll into this study. Around 1200 participants will be enrolled in the study at approximately 120 sites in the United States. Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any intensity per month. There will be an option to take a second dose of study intervention (identical to initial dose), or rescue medication, starting 2 hours after the initial dose. The study duration will be up to 54 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.

Key facts

Study ID

NCT05127954

Run by

AbbVie

People needed

1200

Starts

2022-01-14

Expected to finish

2028-01-01

Last updated by the study team

2025-07-20

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completers of the lead-in Study 3110-305-002 (in the main study or PK cohort) or those who screen failed due to being placebo responders.
• Demonstrated an acceptable degree of compliance with study procedures in the lead-in study and who, in the investigator's clinical judgment, did not experience an AE that may indicate an unacceptable safety risk for this study.

You may not qualify if…

• Requirement for any medication (eg, barbiturates) or diet (eg, grapefruit juice) that is on the list of prohibited concomitant medications that cannot be discontinued or switched to an allowable, alternative medication at Visit 1.
• An ECG with clinically significant abnormalities at Visit 1 as determined by the investigator.
• Clinically significant abnormalities in physical examination at Visit 1, as determined by the investigator.
• Significant risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator; participants should be excluded if they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on the C-SSRS), or report suicidal behavior at Visit 1
• Any medical or other reason (eg, unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study) that, in the investigator's opinion, might indicate that the participant is unsuitable for the study.

Where it is running

• The Center for Clinical Trials - Saraland /ID# 239448 — Saraland, Alabama, United States
• Preferred Research Partners /ID# 238979 — Little Rock, Arkansas, United States
• Advanced Research Center /ID# 238967 — Anaheim, California, United States
• Neuro Pain Medical Center /ID# 239135 — Fresno, California, United States
• Alliance for Research Alliance for Wellness /ID# 233497 — Long Beach, California, United States
• Children's Hospital Los Angeles /ID# 239446 — Los Angeles, California, United States
• Excell Research, Inc /ID# 233495 — Oceanside, California, United States
• Paradigm Clinical Research - San Diego /ID# 269611 — San Diego, California, United States
• Lumos Clinical Research Center /ID# 239018 — San Jose, California, United States
• Pacific Clinical Research Management Group /ID# 238503 — Upland, California, United States
• Sunwise Clinical Research /ID# 238458 — Walnut Creek, California, United States
• Children's Hospital Colorado - Aurora /ID# 239838 — Aurora, Colorado, United States
• IMMUNOe Research Centers /ID# 240846 — Centennial, Colorado, United States
• MCB Clinical Research Centers /ID# 240999 — Colorado Springs, Colorado, United States
• New England Institute for Clinical Research /ID# 239019 — Stamford, Connecticut, United States
• Emerson Clinical Research Inst /ID# 238455 — Washington D.C., District of Columbia, United States
• Encore Medical Research of Boynton Beach LLC /ID# 248720 — Boynton Beach, Florida, United States
• Gulf Coast Clinical Research Center /ID# 233335 — Fort Myers, Florida, United States
• Sarkis Clinical Trials /ID# 233493 — Gainesville, Florida, United States
• Northwest Florida Clinical Research Group, LLC /ID# 244396 — Gulf Breeze, Florida, United States
• A.G.A Clinical Trials /ID# 238409 — Hialeah, Florida, United States
• Encore Medical Research /ID# 247463 — Hollywood, Florida, United States
• Advanced Research Institute of Miami /ID# 240712 — Homestead, Florida, United States
• Auzmer Research /ID# 241514 — Lakeland, Florida, United States
• Rehabilitation & Neurological Services /ID# 240054 — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.